These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 6529866)

  • 1. Verapamil in chronic atrial fibrillation: variable patterns of response in ventricular rate.
    Klein GJ; Twum-Barima Y; Gulamhusein S; Carruthers SG; Donner AP
    Clin Cardiol; 1984 Sep; 7(9):474-83. PubMed ID: 6529866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disposition and pharmacologic effects of R/S-verapamil in patients with chronic atrial fibrillation: an investigation comparing single and multiple dosing.
    Busse D; Fromm MF; Mörike K; Drescher S; Kühlkamp V; Eichelbaum M
    Clin Pharmacol Ther; 2001 May; 69(5):324-32. PubMed ID: 11372000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Superiority of oral verapamil therapy to digoxin in treatment of chronic atrial fibrillation.
    Lang R; Klein HO; Weiss E; David D; Sareli P; Levy A; Guerrero J; Di Segni E; Kaplinsky E
    Chest; 1983 Mar; 83(3):491-9. PubMed ID: 6337787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Regularization of ventricular intervals in atrial fibrillation--electrophysiologic findings on the underlying mechanism].
    Neuss H; Golling FR; Schlepper M; Thormann J; Weissmüller P; Kindler M
    Z Kardiol; 1984 Feb; 73(2):106-12. PubMed ID: 6719983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rate-control drugs affect variability and irregularity measures of RR intervals in patients with permanent atrial fibrillation.
    Corino VD; Ulimoen SR; Enger S; Mainardi LT; Tveit A; Platonov PG
    J Cardiovasc Electrophysiol; 2015 Feb; 26(2):137-41. PubMed ID: 25367150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacokinetics of verapamil in patients with atrial fibrillation.
    Anderson P; BondessoN U; Sylvén C
    Eur J Clin Pharmacol; 1982; 23(1):49-57. PubMed ID: 7128672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Verapamil in atrial fibrillation and atrial flutter.
    Aronow WS; Landa D; Plasencia G; Wong R; Karlsberg RP; Ferlinz J
    Clin Pharmacol Ther; 1979 Nov; 26(5):578-83. PubMed ID: 498700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Verapamil plasma levels and ventricular rate response in patients with atrial fibrillation and flutter.
    Dominic J; McAllister RG; Kuo CS; Reddy CP; Surawicz B
    Clin Pharmacol Ther; 1979 Dec; 26(6):710-4. PubMed ID: 498712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of intravenous diltiazem and verapamil for the acute treatment of atrial fibrillation and atrial flutter.
    Phillips BG; Gandhi AJ; Sanoski CA; Just VL; Bauman JL
    Pharmacotherapy; 1997; 17(6):1238-45. PubMed ID: 9399606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Characteristics of action of various drugs blocking atrioventricular conduction (beta-blockers, verapamil, diltiazem) in constant fibrillation tachyarrhythmia. Is monotherapy optimal?].
    Blagova OV; Nedostup AV
    Ter Arkh; 2006; 78(8):30-8. PubMed ID: 17078214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The beneficial effects of verapamil in chronic atrial fibrillation.
    Klein HO; Pauzner H; Di Segni E; David D; Kaplinsky E
    Arch Intern Med; 1979 Jul; 139(7):747-9. PubMed ID: 454060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Haemodynamic effect of intravenous verapamil in controlled atrial fibrillation.
    Sloman G; Spokes J; Ramshaw J; Vohra J
    Aust N Z J Med; 1975 Oct; 5(5):420-3. PubMed ID: 1061542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolongation of verapamil elimination kinetics during chronic oral administration.
    Schwartz JB; Keefe DL; Kirsten E; Kates RE; Harrison DC
    Am Heart J; 1982 Aug; 104(2 Pt 1):198-203. PubMed ID: 7102502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of oral verapamil on ventricular irregularity in long-standing atrial fibrillation.
    Khalsa A; Olsson B; Henriksson BA
    Acta Med Scand; 1979; 205(1-2):39-47. PubMed ID: 367086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of the atrial rate as a factor modulating ventricular response during atrial fibrillation.
    Climent AM; Guillem MS; Husser D; Castells F; Millet J; Bollmann A
    Pacing Clin Electrophysiol; 2010 Dec; 33(12):1510-7. PubMed ID: 20636310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of digoxin, propranolol, and verapamil on exercise in patients with chronic isolated atrial fibrillation.
    Matsuda M; Matsuda Y; Yamagishi T; Takahashi T; Haraguchi M; Tada T; Kusukawa R
    Cardiovasc Res; 1991 Jun; 25(6):453-7. PubMed ID: 1889058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 24-hour antiarrhythmic effect of conventional and slow-release verapamil in chronic atrial fibrillation.
    Mølgaard H; Bjerregaard P; Jørgensen HS; Klitgaard NA
    Eur J Clin Pharmacol; 1987; 33(5):447-53. PubMed ID: 3428338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical use of oral verapamil in chronic and paroxysmal atrial fibrillation.
    Stern EH; Pitchon R; King BD; Guerrero J; Schneider RR; Wiener I
    Chest; 1982 Mar; 81(3):308-11. PubMed ID: 7056105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beta-blockade and A1-adenosine receptor agonist effects on atrial fibrillatory rate and atrioventricular conduction in patients with atrial fibrillation.
    Corino VD; Holmqvist F; Mainardi LT; Platonov PG
    Europace; 2014 Apr; 16(4):587-94. PubMed ID: 23989533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Verapamil disposition kinetics in chronic atrial fibrillation.
    Kates RE; Keefe DL; Schwartz J; Harapat S; Kirsten EB; Harrison DC
    Clin Pharmacol Ther; 1981 Jul; 30(1):44-51. PubMed ID: 7237897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.